Administration of MDA7, a potent CB2R selective agonist, to AD transgenic amyloid precursor protein/presenilin 1 (APP/PS1) mice was observed to reduce microgliosis, promote Aβ clearance, restore memory performance, synaptic plasticity and Sox2 expression, a transcription factor expressed by NSCs in the DG [318,332]. The gene discussed is APP; the disease is Alzheimer disease.